Print this page
-
An Escalation/Expansion, Open Label, Multicenter Study of Iadademstat and Gilteritinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (R/R AML) with FMS-Like Tyrosine Kinase Mutation (FLT3 mut+): The FRIDA Study.
Protocol: 022301Principal Investigator:
-
Neil Palmisiano
Applicable Disease Sites: Myeloid and Monocytic Leukemia -
A Phase 1/2, Open-Label, Dose-Escalation, Dose-Expansion Study of DSP- 5336 in Adult Acute Leukemia Patients with and without Mixed Lineage Leukemia (MLL) Rearrangement or Nucleophosmin 1 (NPM1) Mutation.
Protocol: 022303Principal Investigator:
-
Neil Palmisiano
Applicable Disease Sites: Leukemia, other -
Phase 1 Study of Venetoclax/Azacitidine or Venetoclax in Combination with Ziftomenib (KO-539) or Standard Induction Cytarabine/ Daunorubicin (7+3) Chemotherapy in Combination with Ziftomenib for the Treatment of Patients with Acute Myeloid Leukemia.
Protocol: 022305Principal Investigator:
-
Neil Palmisiano
Applicable Disease Sites: Myeloid and Monocytic Leukemia -
Master Screening and Reassessment Protocol (MSRP) for Tier Advancement in the NCI myeloMATCH Clinical Trials.
Protocol: 022404Principal Investigator:
-
Neil Palmisiano
Applicable Disease Sites: Leukemia, other -
A Phase 2 Study of Inotuzumab Ozogamicin in Children and Young Adults with Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL).
Protocol: 111707Principal Investigator:
-
Archana Sharma
Applicable Disease Sites: Lymphoid Leukemia -
Characterization of Brain Dysfunction During Development in Survivors of Childhood Acute Lymphoblastic Leukemia.
Protocol: 112002Principal Investigator:
-
Peter D. Cole
Applicable Disease Sites: Leukemia, not otherwise specified -
Pediatric Acute Leukemia (PedAL) Screening Trial: Developing New Therapies for Relapsed Leukemias.
Protocol: 112204Principal Investigator:
-
Richard A Drachtman
Applicable Disease Sites: Leukemia, not otherwise specified -
A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy with Immuno-Oncology Therapy for Children and Adults with Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma.
Protocol: 112305Principal Investigator:
-
Richard A Drachtman
Applicable Disease Sites: Hodgkin's Lymphoma -
A Phase 2 Study of SNDX-5613 in Combination with Chemotherapy for Patients with Relapsed or Refractory KMT2A-Rearranged Infant Leukemia.
Protocol: 112402Principal Investigator:
-
Richard A Drachtman
Applicable Disease Sites: Leukemia, other -
Improving Chemotherapy-Induced Nausea Control Through Bright Ideas®-CIN Training: A Feasibility Study in Children Receiving Oral Chemotherapy.
Protocol: 132104Principal Investigator:
-
Katie Devine
Applicable Disease Sites: Leukemia, not otherwise specified
Leukemia, other -
Exploring Patient and Caregiver Perspectives and Experiences with Financial Toxicity.
Protocol: 132105Principal Investigator:
-
Biren Saraiya
Applicable Disease Sites: Hodgkin's Lymphoma
Leukemia, not otherwise specified
Leukemia, other
Myeloid and Monocytic Leukemia -
Characterizing Lymphoma Survivors Experiences, Needs, and Preferences During the Transition to Cancer Survivorship: The Survivor Health Check Program Development Trial.
Protocol: 132203Principal Investigator:
-
Sharon Manne
Applicable Disease Sites: Hodgkin's Lymphoma
Non-Hodgkin's Lymphoma -
Needs Survey for Childhood, Adolescent, Young Adults (CAYA) Cancer Survivors, Their Siblings, and Parents/Caregivers.
Protocol: 132213Principal Investigator:
-
Katie Devine
Applicable Disease Sites: Any Site
Bones and Joints
Brain and Nervous System
Hodgkin's Lymphoma
Leukemia, not otherwise specified
Leukemia, other
Non-Hodgkin's Lymphoma